Gene expression analysis of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type
Ontology highlight
ABSTRACT: Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the changes in the gene expression profile, that accompany resistance development, we treated the erlotinib sensitive non-small cell lung cancer cell line H358 with increasing concentrations of erlotinib (1-5µM) for several weeks (H358res). In parallel, we kept H358 with the same concentrations of the vehicle DMSO (H358co). After ten weeks of treatment, when the H358res stably grew under 5µM erlotinib, total RNA of both cell lines was harvested and hybridized.
ORGANISM(S): Homo sapiens
SUBMITTER: Simone Brabletz
PROVIDER: E-MTAB-3387 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA